Farmacéuticas Grünenthal y Merz Terapéutica firman alianza milenio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from milenio.com Daily Mail and Mail on Sunday newspapers.
Winhealth Pharma and Merz Collaborate on Hepa-Merz to benefit patients with liver disease in China
HANG ZHOU, China, March 9, 2021 /PRNewswire/ On Feb. 26
th, 2021, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as Winhealth Pharma ) signed a strategic cooperation agreement with Merz Pharmaceuticals GmbH (hereinafter referred to as Merz ). The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz (L-ornithine L-aspartate, an important product under Merz product portfolio) in China.
About L-ornithine L-aspartate and hepatic encephalopathy (HE)
L-ornithine L-aspartate (LOLA) is a stable salt of two amino acids that stimulates ammonia detoxification by increasing urea synthesis in the liver and muscle, thereby reducing the blood ammonia content in the brain which causes hepatic encephalopathy in cirrhotic patients.
09 marzo 2021 06:48
Fonte: Adnkronos
#chimica-e-farmacia
HANG ZHOU, China, March 9, 2021 /PRNewswire/ On Feb. 26th, 2021, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as Winhealth Pharma ) signed a strategic cooperation agreement with Merz Pharmaceuticals GmbH (hereinafter referred to as Merz ). The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz® (L-ornithine L-aspartate, an important product under Merz product portfolio) in China.
About L-ornithine L-aspartate and hepatic encephalopathy (HE)
L-ornithine L-aspartate (LOLA) is a stable salt of two amino acids that stimulates ammonia detoxification by increasing urea synthesis in the liver and muscle, thereby reducing the blood ammonia content in the brain which causes hepatic encephalopathy in cirrhotic patients.
Merz Healthcare Breaks Even Despite COVID-19 Pandemic in Fiscal Year 2019/20
Partnership with Gwyneth Paltrow and investment in start-up Brooklyn Soap Company
Investments in the new organizational structure pay off in times of COVID-19: Focus on customer needs have proven their worth
Merz Healthcare in Frankfurt is a globally operating, diversified company with three independently operating businesses: Merz Aesthetics, Merz Therapeutics and Merz Consumer Care.
In fiscal year 2019/20, Merz Healthcare revenue amounted to EUR 981.5 million, a moderate decline of 10.3% compared to the prior-year figure.
The operating profit in the past fiscal year was EUR 38.8 million. The decline compared with the prior-year EBIT was expected due to the COVID-19 crisis. After an excellent start to the fiscal year, COVID-19 contributed to the reduction in earnings, particularly in the second half of the year.
Merz Healthcare Breaks Even Despite COVID-19 Pandemic in Fiscal Year 2019/20 FRANKFURT, Germany (Business Wire) Merz Healthcare in Frankfurt is a globally operating, diversified company with three independently operating businesses: Merz Aesthetics, Merz Therapeutics and Merz Consumer Care.
In fiscal year 2019/20, Merz Healthcare revenue amounted to EUR 981.5 million, a moderate decline of 10.3% compared to the prior-year figure.
The operating profit in the past fiscal year was EUR 38.8 million. The decline compared with the prior-year EBIT was expected due to the COVID-19 crisis. After an excellent start to the fiscal year, COVID-19 contributed to the reduction in earnings, particularly in the second half of the year.